TY  - BOOK
AU  - Müller,Gerhard
AU  - Klebl,Bert
ED  - Wiley InterScience (Online service)
TI  - Protein kinases as drug targets
T2  - Methods and principles in medicinal chemistry
SN  - 9783527633470
AV  - RM666.E548 P76 2011
U1  - 615.798 22
PY  - 2011///
CY  - Weinheim, Chichester
PB  - Wiley-VCH, John Wiley [distributor]
KW  - Protein kinases
KW  - Inhibitors
KW  - Antineoplastic agents
KW  - Development
KW  - Protein Kinase Inhibitors
KW  - therapeutic use
KW  - Drug Delivery Systems
KW  - Drug Discovery
KW  - MEDICAL
KW  - Pharmacology
KW  - bisacsh
KW  - Electronic books
N1  - Includes bibliographical references and index; In vitro characterization of small-molecule kinase inhibitors -- Screening for kinase inhibitors: from biochemical to cellular assays -- Dissecting phosphorylation networks: the use of analogue-sensitive kinases and more specific kinase inhibitors as tools -- Rational drug design of kinase inhibitors for signal transduction therapy -- Kinaes inhibitors in signal transduction therapy -- Design principles of deep pocket-targeting protein kinase inhibitors -- From discovery to clinic: aurora kinase inhibitors as novel treatments for cancer -- Discovery and design of protein kinase inhibitors: targeting the cell cycle in oncology -- Medicinal chemistry approaches for the inhibition of the p38 MAPK pathway -- Cellular protein kinases as antiviral targets -- Prospects for TB therapeutics targeting mycobacterium tuberculosis phosphosignaling networks
N2  - With Kinase inhibitors being widely seen as the long-sought 'magic bullet' to conquer cancer, this fully comprehensive guide to kinase inhibitor drug development covers the entire drug pipeline from target identification to compound development and clinical application. Volume 1 focuses upon the medicinal chemistry of kinase drugs, from target identification to lead optimization, and contains numerous contributions from large and small pharmaceutical companies. Volume 2 surveys current and future therapeutic application areas for kinase inhibitor drugs, with a strong focus on oncology drugs, as this is the most important therapeutic field for these drugs. In addition, all six currently approved kinase inhibitor drugs (small molecules and antibodies) are described, and their performances in clinical practice are discussed
UR  - http://dx.doi.org/10.1002/9783527633470
ER  -